Kyowa Kirin to receive ~$83.35M up front & an additional fee upon purchase of the remaining share & IP of the portfolio along with royalties. The transaction is expected to be close in Q2’23
Grünenthal will hold a 51% majority share in the new company & get an option to acquire the remaining shares after Jan 2026. Kyowa Kirin will own a 49% share & will initially retain the IP related to the portfolio
13 brands from 6 therapeutic areas are included in the JV collaboration primarily focused on pain management which incl.: Abstral & PecFent for cancer pain, Moventig for opioid-induced constipation, and Adcal-D3 for osteoporosis. The portfolio is available in 7 EU markets through affiliates & in multiple additional territories globally through a network of partners
Ref: Businesswire | Image: Kyowa Kirin
